Tenvir-em
Tenofovir Disoproxil · Emtricitabine
Tenofovir and emtricitabine tablets for HIV and pre-exposure prophylaxis. Combining two antivirals lowers the risk of resistance.
- Categories
- HIV Management · Antivirals
- Active ingredients
- Tenofovir Disoproxil · Emtricitabine
- Route
- Oral use
- Form
- Tablet
- Strengths
- 300mg + 200mg
Prescription and consultation requirements for Tenvir-em vary by destination and are determined by the fulfilment partner.
Tenvir-em details
- Alternative names
- tenofovir, emtricitabine
- Therapeutic class
- Nucleoside Reverse Transcriptase Inhibitor Combination
- Pharmacological class
- Antiretroviral Combination
- Minor side effects
- nausea; headache; fatigue
- Moderate side effects
- bone density reduction; elevated cholesterol; diarrhoea
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Cipla Ltd
- Onset Time
- 1–2 weeks
- Duration
- 24 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- Acyclovir; Ganciclovir; NSAIDs
- Age restrictions
- Approved for adolescents and adults weighing over thirty-five kilograms.
Contraindications
uncontrolled renal impairment; unconfirmed HIV-negative status when used for PrEP
Serious side effects
lactic acidosis, requires immediate medical attention; severe hepatomegaly with steatosis, requires immediate medical attention
Patient summary
Tenofovir and emtricitabine tablets for HIV and pre-exposure prophylaxis. Combining two antivirals lowers the risk of resistance.
Mechanism of action
Combines two reverse transcriptase inhibitors to cause early viral DNA chain termination during viral replication.
Pregnancy and breastfeeding
Pregnancy: Crucial for prevention of transmission. Breastfeeding: Avoid in HIV-positive patients.